Cardiomyopathy is classified to ICD-10-CM category I42, Cardiomyopathy. ICD-10-CM allows the different types of cardiomyopathy to have a unique code.
ICD-10-CM allows the different types of cardiomyopathy to have a unique code. The following are the codes included under category I42: • I42.1, Obstructive hypertrophic cardiomyopathy (includes hypertrophic subaortic stenosis);
The classic description of cardiomyopathy related to chemotherapy results from anthracyclines. With this particular class of drugs, the onset of cardiomyopathy can occur acutely (during or shortly after treatment), subacutely (days or weeks after treatment), or chronically (months to years after treatment).
This type most commonly occurs in childhood. Code 425.4 is assigned for hypertrophic cardiomyopathy unless the condition is documented as obstructive, which is classified to code 425.1. Congenital hypertrophic obstructive cardiomyopathy is assigned to code 746.84.
7.
ICD-10 code I42. 0 for Dilated cardiomyopathy is a medical classification as listed by WHO under the range - Diseases of the circulatory system .
Causes of Cardiomyopathy in Cancer Patients They include doxorubicin (Adriamycin® and Rubex®), daunorubicin (Cerubidine®), epirubicin (Ellence®), and idarubicin (Idamycin®). You're more likely to get cardiomyopathy from these medications if you get high doses of them.
Cardiomyopathy, unspecified9: Cardiomyopathy, unspecified.
Dilated cardiomyopathy is a type of heart muscle disease that causes the heart chambers (ventricles) to thin and stretch, growing larger. It typically starts in the heart's main pumping chamber (left ventricle). Dilated cardiomyopathy makes it harder for the heart to pump blood to the rest of the body.
ischemic and dilated cardiomyopathy, code I25. 5, Ischemic cardiomyopathy, is advised. Dilated cardiomyopathy is most commonly the result of ischemic cardiomyopathy; the underlying disease should be reported. "congestive dilated cardiomyopathy," should be reported with I42.
Some types of chemotherapy (primarily in a class of drugs called anthracyclines) weaken the heart muscle from a buildup of calcium and other chemical reactions in the body that release harmful free radicals. Thus, chemotherapy side effects include cardiomyopathy (an enlargement) or congestive heart failure.
It is often reversible after treatment discontinuation and can be tolerated once again, if indicated, after recovery (10). The risk of developing trastuzumab cardiotoxicity increases in patients who receive concurrent anthracycline therapy especially if the cumulative doxorubicin dose is > 300 mg/m².
Of the conventional agents, anthracyclines have the most data concerning management and risk of cardiotoxicity. For that reason, agents are recommended to reduce the incidence and severity of cardiotoxicity in patients receiving anthracyclines.
Other persistent atrial fibrillationICD-10 code I48. 19 for Other persistent atrial fibrillation is a medical classification as listed by WHO under the range - Diseases of the circulatory system .
Coding for Cardiomyopathy in ICD-10-CM I42. 9, Cardiomyopathy, unspecified (includes cardiomyopathy [primary] [secondary] NOS).
Cardiomyopathy (kahr-dee-o-my-OP-uh-thee) is a disease of the heart muscle that makes it harder for the heart to pump blood to the rest of the body. Cardiomyopathy can lead to heart failure. The main types of cardiomyopathy include dilated, hypertrophic and restrictive cardiomyopathy.
New research suggests that the widely used chemotherapy drug doxorubicin may cause heart toxicity, potentially leading to congestive heart failure.
Doxorubicin appears to induce toxic damage to the mitochondria of cardiomyocytes. Several mitochondrial enzymes such as NADH dehydrogenase, cytochrome P-450 reductase and xanthine oxidase are involved in generating oxygen free radicals (reactive oxygen species) [3,23,24,25].
Traditional and novel chemotherapy agents can damage the heart or peripheral blood vessels, or cause problems with clotting or blood lipids. Some serious cardiovascular effects occur while the chemotherapy is being given; others appear long after cancer has become a distant memory.
Doxorubicin is a highly effective anticancer agent but causes cardiotoxicity in many patients. The mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood.
Free, official coding info for 2022 ICD-10-CM I42.9 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
Free, official coding info for 2022 ICD-10-CM I42 - includes detailed rules, notes, synonyms, ICD-9-CM conversion, index and annotation crosswalks, DRG grouping and more.
ICD Code I42 is a non-billable code. To code a diagnosis of this type, you must use one of the ten child codes of I42 that describes the diagnosis 'cardiomyopathy' in more detail.
A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself. Cardiomyopathies are classified according to their predominant pathophysiological features (dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy) or their etiological/pathological factors (cardiomyopathy, alcoholic; endocardial fibroelastosis).
A type 2 excludes note represents "not included here". A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( I42) and the excluded code together.
A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself. Cardiomyopathies are classified according to their predominant pathophysiological features (dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy) or their etiological/pathological factors (cardiomyopathy, alcoholic; endocardial fibroelastosis).
A type 2 excludes note represents "not included here". A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( I42) and the excluded code together.
I42 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself. Cardiomyopathies are classified according to their predominant pathophysiological features (dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy) or their etiological/pathological factors (cardiomyopathy, alcoholic; endocardial fibroelastosis).
The 2022 edition of ICD-10-CM I42.9 became effective on October 1, 2021.
There are three types of cardiomyopathy: • Dilated cardiomyopathy (ICD-9-CM code 425.4) is the most common type in which the left ventricle becomes enlarged and can no longer pump blood throughout the body. This type generally occurs in middle-aged people.
Dilated cardiomyopathy may be treated with the following medications: an angiotensin-converting enzyme inhibitor to improve the heart’s pumping ability; an angiotensin receptor blocker; digoxin/digitalis to increase the strength of the heart muscle contractions and possibly slow the heartbeat; a diuretic to reduce fluid retention; or a beta blocker to improve cardiac function.
Hypertropic cardiomyopathy may be treated with medications such as beta blockers and calcium channel blockers to slow the heart’s pumping action and stabilize heart rhythms. If medications don’t work, then one of the following procedures may be recommended: septal myectomy, septal ablation, pacemaker implantation, or an implantable cardioverter defibrillator.
If the cardiomyopathy has progressed to end stage, the patient will need a heart transplant.
This type of cardiomyopathy usually affects older people. Physicians may use the term “congestive cardiomyopathy, ” which is also referred to as dilated cardiomyopathy and is characterized by ventricular dilation, contractile dysfunction, and symptoms of chronic heart failure (CHF).
After a thorough physical examination, the physician may perform the following diagnostic tests if cardiomyopathy is suspected: a chest x-ray to determine whether the heart is enlarged; an echocardiogram to view the size of the heart and the motion as it beats; an electrocardiogram to show disturbances in the heart’s electrical activity to detect abnormal rhythms and areas of injury; cardiac MRI; cardiac catheterization to measure pressure within the heart chambers; or blood tests such as B-type natriuretic peptide, a protein produced in the heart that rises when the heart is subjected to the stress of CHF.
For The Record. Vol. 23 No. 10 P. 27. Cardiomyopathy is a progressive disease of the heart muscle with no known etiology. The condition makes it difficult for the heart to pump blood throughout the body. Although it may develop secondarily to a disease elsewhere in the body, such as coronary artery disease or valvular heart disease, ...
With this particular class of drugs, the onset of cardiomyopathy can occur acutely (during or shortly after treatment), subacutely (days or weeks after treatment), or chronically (months to years after treatment).
The incidence of cardiomyopathy associated with trastuzumab is reported to be 7% to 33%, and a significant portion of these patients can have asymptomatic LV dysfunction. Age, prior exposure to anthracycline, borderline EF before treatment, and presence of cardiovascular risk factors seem to be the most important risk factors for trastuzumab-induced cardiomyopathy.
For example, 65% of patients who receive anthracycline for childhood leukemia show evidence of LV dysfunction up to 15 years after completion of chemotherapy. Several factors such as cumulative dose, rate of drug administration, concomitant mediastinal radiation, age, female gender, and preexisting heart disease have been reported to be associated with higher incidence of CIM due to anthracyclines.
“Cardiotoxicity” related to chemotherapy is not limited to left ventricular dysfunction, and it can include a much broader spectrum of cardiovascular side effects such as arrhythmias, Q–T prolongation, hypertension, thrombosis, or even pericardial disease.
The clinical manifestation of CIM can range from asymptomatic with abnormalities seen on imaging or cardiac biomarkers to immediate life-threatening symptoms or even sudden cardiac death. Common clinical findings detected in asymptomatic subclinical phase can be as subtle and include: 1. Mild blood pressure changes.
It is imperative for the oncologist and cardiologist treating a patient with cancer to have open communication and cooperation to improve the quality of life of these patients. Cardiologists need to use their expertise to identify and manage cardiac injury to maximize the potential for successful chemotherapy.
In 2002 the Cardiac Review and Evaluation Committee in the trastuzumab clinical trials established a definition of chemotherapy-induced cardiomyopathy (CIM). The following criteria established a diagnosis of CIM:
A group of diseases in which the dominant feature is the involvement of the cardiac muscle itself. Cardiomyopathies are classified according to their predominant pathophysiological features (dilated cardiomyopathy; hypertrophic cardiomyopathy; restrictive cardiomyopathy) or their etiological/pathological factors (cardiomyopathy, alcoholic; endocardial fibroelastosis).
A type 2 excludes note represents "not included here". A type 2 excludes note indicates that the condition excluded is not part of the condition it is excluded from but a patient may have both conditions at the same time. When a type 2 excludes note appears under a code it is acceptable to use both the code ( I42) and the excluded code together.